Skip to main content

Table 1 Patients’ characteristic data

From: Pharmacokinetic modeling of [18F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds

Patient Sex Age (months) Weight (kg) Activity (MBq) Acquisition time after injection (min) Provisional/suspected diagnosis (reason for PET/CT examination)
1 F 11 8.3 51.8 93 Rhabdomyosarcomaa
2 F 16 10.4 57.3 83 Neurofibromatosis 1 (abdominal/right flank pain)
3 F 3 4.5 27.1 94 Ewing’s sarcomab
4 F 4 7.3 38.4 79 Suspected pelvic carcinoma
5 F 10 5.9 31.0 69 Retroperitoneal sarcoma s/p chemotherapy (assess for tumor activity)
6 F 3 4.0 25.9 60 Infantile adenocarcinomab
7 F 0.5 3.1 19.6 60 Infantile myofibromatosisa
8 F 16 11.6 64.0 84 Rhabdomyosarcomaa
9 M 6 10.0 58.8 126 Suspected left scalp Ewing’s sarcoma
10 M 9 7.7 44.4 97 Suspected pheochromocytomaa
11 M 8 9.6 50.0 125 Suspected malignant liver lesionb
12 F 36 12.4 80.3 74 Rhabdomyosarcoma s/p therapya
13 F 36 12.0 69.5 86 Rhabdomyosarcoma s/p therapyb
14 F 36 11.6 64.0 71 Rhabdomyosarcoma s/p therapyb
15 F 12 9.1 51.0 66 Infantile fibrosarcoma of pelvis s/p therapya
16 M 60 18.0 64.2 70 Diffuse large B cell lymphoma stage IVa
17 M 7 8.6 30.6 78 Hodgkin’s lymphoma s/p chemotherapya
18 F 48 16.0 91.2 81 Localized Ewing’s sarcomaa
19 M 48 15.1 82.9 73 Neurofibromatosis 1 (tumor activity evaluation)
20 F 13 7.3 40.7 60 Suspected malignant pelvic massb
21 M 24 12.4 81.2 85 High-risk neuroblastoma s/p therapya
22 M 9 10.5 94.8 113 Multifocal inflammatory myofibroblastic tumor of the lungs s/p chemotherapya
23 F 10 9.9 58.8 109 B cell lymphomaa
24 F 7 8.1 48.1 117 Anaplastic large-cell lymphoma s/p therapya
25 F 11 7.0 37.4 88 Hepatoblastoma s/p chemotherapya
26 F 11 10.5 57.1 106 Suspected left renal cell carcinomaa
27 M 23 12.6 79.1 89 Suspected rhabdomyosarcoma
28 M 24 12.7 75.6 69 Right calf alveolar rhabdomyosarcomaa
29 M 36 13.8 81.4 117 Stage IV neuroblastoma s/p therapya
30 M 36 14.3 74.0 83 Stage IV neuroblastoma s/p therapya
31 M 48 21.7 121.4 82 Rhabdomyosarcomaa
32 M 60 22.0 125.8 119 Spinal neurofibromaa
33 F 60 20.1 116.6 81 Suspected neck LN in thyroid cancerb
34 M 60 16.6 92.9 83 Metastatic glomus tumora
35 M 60 16.8 96.9 75 Malignant rhabdoid tumor s/p therapya
  1. aEvaluation for staging and/or response (post therapy)
  2. bEvaluation for metastasis